TRINITY: Rova-T for relapsed SCLC
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Lung cancer immunotherapy test standardization: the Blueprint PD-L1 IHC Assay Comparison Project
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
Nonmetastatic CRPC: meeting an unmet need